Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) has been given a consensus recommendation of “Buy” by the thirteen research firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and ten have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $51.90.
DCPH has been the topic of several recent analyst reports. SunTrust Banks increased their target price on shares of Deciphera Pharmaceuticals to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Cantor Fitzgerald increased their target price on shares of Deciphera Pharmaceuticals from $43.00 to $55.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Leerink Swann reiterated a “positive” rating and issued a $29.00 target price (up from $20.00) on shares of Deciphera Pharmaceuticals in a research note on Wednesday, August 14th. HC Wainwright initiated coverage on shares of Deciphera Pharmaceuticals in a research note on Thursday, October 3rd. They issued a “buy” rating and a $60.00 target price on the stock. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $65.00 target price (up from $50.00) on shares of Deciphera Pharmaceuticals in a research note on Wednesday, August 14th.
NASDAQ DCPH opened at $32.54 on Monday. Deciphera Pharmaceuticals has a 1 year low of $18.55 and a 1 year high of $42.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.26 and a quick ratio of 7.26. The stock has a market capitalization of $1.61 billion, a PE ratio of -11.54 and a beta of 1.89. The company’s 50 day simple moving average is $35.54 and its two-hundred day simple moving average is $26.77.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its earnings results on Friday, August 2nd. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.12) by $0.56. The firm had revenue of $25.00 million during the quarter, compared to analysts’ expectations of $20.00 million. On average, research analysts anticipate that Deciphera Pharmaceuticals will post -4.05 EPS for the current year.
In other news, major shareholder New Leaf Venture Management Ii sold 350,000 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $36.42, for a total transaction of $12,747,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Daniel C. Martin sold 3,000 shares of the firm’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $35.56, for a total transaction of $106,680.00. In the last 90 days, insiders have sold 576,107 shares of company stock worth $21,748,018. Corporate insiders own 7.02% of the company’s stock.
Several institutional investors have recently bought and sold shares of DCPH. BlackRock Inc. raised its position in Deciphera Pharmaceuticals by 25.6% in the 2nd quarter. BlackRock Inc. now owns 1,531,844 shares of the company’s stock worth $34,543,000 after purchasing an additional 311,870 shares during the period. Point72 Asset Management L.P. purchased a new position in Deciphera Pharmaceuticals in the 2nd quarter worth $4,606,000. Alps Advisors Inc. purchased a new position in Deciphera Pharmaceuticals in the 2nd quarter worth $1,802,000. Marshall Wace North America L.P. raised its position in Deciphera Pharmaceuticals by 4,025.4% in the 1st quarter. Marshall Wace North America L.P. now owns 57,714 shares of the company’s stock worth $1,340,000 after purchasing an additional 56,315 shares during the period. Finally, Eversept Partners LP raised its position in Deciphera Pharmaceuticals by 21.9% in the 2nd quarter. Eversept Partners LP now owns 305,233 shares of the company’s stock worth $6,883,000 after purchasing an additional 54,801 shares during the period. Hedge funds and other institutional investors own 45.68% of the company’s stock.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
See Also: QQQ ETF
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.